Hurst D L, Rolan T D
Department of Neurology, Texas Tech University School of Medicine, Lubbock, USA.
J Child Neurol. 1995 Mar;10(2):134-6. doi: 10.1177/088307389501000215.
Based on the initial successful use of felbamate for infantile spasms in an infant with tuberous sclerosis, three additional infants with infantile spasms of different etiologies who had failed conventional therapies were treated with felbamate. Three of the four patients have shown complete resolution of infantile spasms. All responding patients did so within 1 week of starting felbamate. The one treatment failure had an initial reduction of seizure frequency and severity but has not maintained that response long term. Controlled studies are needed to firmly establish that felbamate is both safe and effective for the treatment of infantile spasms. As these cases document, felbamate is currently available for use in infantile spasms, and the frequent conversion of infantile spasms to Lennox-Gastaut syndrome, for which felbamate is approved, makes its use in infantile spasms logical.
基于氨己烯酸在一名患有结节性硬化症的婴儿中首次成功用于治疗婴儿痉挛症，另外三名患有不同病因的婴儿痉挛症且传统治疗失败的婴儿接受了氨己烯酸治疗。四名患者中有三名婴儿痉挛症已完全缓解。所有有反应的患者在开始使用氨己烯酸的1周内就出现了这种情况。唯一的治疗失败案例是最初癫痫发作频率和严重程度有所降低，但长期未维持这种反应。需要进行对照研究以确定氨己烯酸治疗婴儿痉挛症是否安全有效。正如这些病例所记录的，氨己烯酸目前可用于治疗婴儿痉挛症，而且婴儿痉挛症经常转变为氨己烯酸已获批准用于治疗的伦诺克斯-加斯托综合征，这使得氨己烯酸用于治疗婴儿痉挛症具有合理性。
